PT3541784T - Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical - Google Patents
Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica corticalInfo
- Publication number
- PT3541784T PT3541784T PT178077798T PT17807779T PT3541784T PT 3541784 T PT3541784 T PT 3541784T PT 178077798 T PT178077798 T PT 178077798T PT 17807779 T PT17807779 T PT 17807779T PT 3541784 T PT3541784 T PT 3541784T
- Authority
- PT
- Portugal
- Prior art keywords
- modulators
- derivatives useful
- azetidine derivatives
- novel azetidine
- cortical
- Prior art date
Links
- 150000001539 azetidines Chemical class 0.000 title 1
- 230000000768 catecholaminergic effect Effects 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3541784T true PT3541784T (pt) | 2023-11-22 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178077798T PT3541784T (pt) | 2016-11-18 | 2017-11-17 | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| CN121511082A (zh) | 2023-07-06 | 2026-02-10 | 综合研究实验室瑞典股份公司 | 用于治疗和/或预防病理性淡漠的3-(2,3-二氟苯氧基)氮杂环丁烷或其药学上可接受的盐 |
| EP4739654A1 (en) | 2023-07-06 | 2026-05-13 | Integrative Research Laboratories Sweden AB | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638939A2 (en) * | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) * | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| WO2010058017A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| WO2010058019A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| JP2012515760A (ja) | 2009-01-20 | 2012-07-12 | ファイザー・インク | 置換ピラジノンアミド |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| AU2011218167B2 (en) * | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| KR101626681B1 (ko) | 2011-06-07 | 2016-06-01 | 화이자 인코포레이티드 | 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도 |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| EP2807163B1 (en) * | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| EP3186224B1 (en) | 2014-08-27 | 2021-04-21 | F. Hoffmann-La Roche AG | Substituted azetidine derivatives as taar ligands |
| EP3215500A1 (en) * | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
| HK1245251B (en) | 2015-05-20 | 2020-04-24 | 综合研究实验室瑞典股份公司 | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission |
| CN108026030B (zh) | 2015-09-18 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| TWI752098B (zh) * | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
-
2017
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10875829B1 (en) | 2020-12-29 |
| PL3541784T3 (pl) | 2024-03-11 |
| EP3541784A1 (en) | 2019-09-25 |
| DK3541784T3 (en) | 2023-10-23 |
| ES2962865T3 (es) | 2024-03-21 |
| WO2018091687A1 (en) | 2018-05-24 |
| JP6990702B2 (ja) | 2022-01-13 |
| CN109963834B (zh) | 2023-04-14 |
| FI3541784T3 (fi) | 2023-10-02 |
| JP2019535715A (ja) | 2019-12-12 |
| DK3541784T5 (da) | 2024-09-16 |
| CN109963834A (zh) | 2019-07-02 |
| EP3541784B1 (en) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500016I1 (hu) | Diaril-makrociklusok mint proteinkináz-modulátorok | |
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| IL304618A (en) | Modulators of pcsk9 expression | |
| ZA201802150B (en) | Compounds useful as modulators of trpm8 | |
| EP3408268B8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| EP3230956A4 (en) | Augmentation of stop-motion content | |
| IL252554A0 (en) | A history of mutated 2-anilinopyrimidines as egfr modulators | |
| PT3131902T (pt) | Compostos como moduladores de ror gama | |
| IL267993A (en) | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | |
| HUE056357T2 (hu) | Szobetirom származékok | |
| EP3180347A4 (en) | Synthesis of cephalosporin compounds | |
| IL273237A (en) | Novel heterocyclic compounds as MGLUR7 modulators | |
| DK3541784T3 (en) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| GB201409783D0 (en) | Phthalimide derivatives as modulators of WNT pathway | |
| ZA201707936B (en) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| HK40001214A (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| AU2015904123A0 (en) | Augmentation of connective tissue | |
| AU2014903769A0 (en) | Brachial effects of infarcts |